Incyte Biosciences Denmark ApS: Financial statements 2017
CVR: 35818790
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
Incyte Biosciences Denmark ApS (CVR 35818790) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 2,043,465 and a net result of DKK 46,870 compared with DKK 25,251 the year before. That is an increase of 36.7% compared with the year before. Equity in the 2017 report amounted to DKK 154,002. The solvency ratio was 8.4%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 2,043,465
- Profit/Loss
- DKK 46,870
- Equity
- DKK 154,002
- Total Assets
- DKK 1,825,215
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 2M | 47K | 154K | 1 |
| 2016 | - | 1.5M | 25K | 107K | - |
| 2015 | - | 1.5M | 26K | 82K | - |
Official annual report
Keep an eye on Incyte Biosciences Denmark ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of May 15, 2017, is registered as an owner of Incyte Biosciences Denmark ApS with an ownership share of 100%.
Incyte Biosciences Denmark ApS has published its annual report for 2016. Gross profit came to DKK 1,494,675, and the net result was DKK 25,251.
About Incyte Biosciences Denmark ApS
Incyte Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Frederiksberg C, founded in 2014. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ARIAD PHARMACEUTICALS (DENMARK) ApS. The management consists of Ebba Cecilia Bröms. The board consists of Lee Jason Heeson (chair) and Ebba Cecilia Bröms. The company is owned by Incyte Biosciences International Sàrl. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. Equity in the 2025 report amounted to DKK 2,328,496.